Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNT1 | O60563 | 12/20 | 0.46 |
| ▸ | CDK9 | P50750 | 12/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.42 |
| ▸ | PDE5A | O76074 | 2/20 | 0.40 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.38 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.38 |
| ▸ | QDPR | P09417 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4564150 | 0.77 | AMY1A (0.45) | PDE5A | |
| SCHEMBL5066917 | 0.77 | GRM5 (0.47) | CCNT1CDK9SCN9A | |
| SCHEMBL31348179 | 0.73 | CCNT1 (0.57) | CCNT1CDK9HTR2CEHMT2EHMT1 | |
| SCHEMBL614978 | 0.73 | CCNT1 (0.57) | CCNT1CDK9HTR2CEHMT2EHMT1 | |
| SCHEMBL5067573 | 0.72 | PARP1 (0.41) | CCNT1CDK9 | |
| SCHEMBL4563904 | 0.69 | HTR7 (0.47) | HTR2C | |
| SCHEMBL14012673 | 0.68 | DRD4 (0.36) | PDE5A | |
| SCHEMBL938466 | 0.68 | GUSB (0.55) | PDE5A | |
| SCHEMBL22323763 | 0.68 | PDE5A (0.52) | PDE5A | |
| SCHEMBL6248434 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338437-B2 | Methyl transferase inhibitors; antiproliferative agents; antiinflammatory agents; immunotherapy; infection therapy | METHYLGENE INC. (CA) | 2012-12-25 | — | — | US | disclosed |
| US-20080280925-A1 | Amines as Small Molecule Inhibitors | METHYLGENE INC. | 2008-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280925-A1 | Amines as Small Molecule Inhibitors | CARM1, PRMT1, PRMT3 | CCNT1 940/4885CDK9 218/4885SCN9A 2629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.